Treatment of Pancreatic Cancer Syracuse NY

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Howard Jay Williams, MD
(315) 479-6626
101 Union Ave Ste 705
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Case Western Reserve Univ Sch Of Med, Cleveland Oh 44106
Graduation Year: 1985

Data Provided by:
Sanford Posnick Temes, MD
(315) 479-6626
101 Union Ave Ste 705 Physician Office Bldg
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1972
Hospital
Hospital: St Josephs Hospital Health Cen, Syracuse, Ny
Group Practice: Syracuse Urology Assoc

Data Provided by:
Philip Ronald Kreitzer, MD
(315) 479-6626
101 Union Avenue Ste 705 Physicians Office Buildin
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Albany Med Coll, Albany Ny 12208
Graduation Year: 1980
Hospital
Hospital: St Josephs Hospital Health Cen, Syracuse, Ny
Group Practice: Syracuse Urology Assoc

Data Provided by:
Oleg Shapiro, MD
(315) 464-6106
750 E Adams St
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Richard Martin Kronhaus, MD
(315) 471-0190
739 Irving Ave Ste 600
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Univ Di Bologna, Fac Di Med E Chirurgia, Bologna, Italy
Graduation Year: 1977
Hospital
Hospital: St Josephs Hospital Health Cen, Syracuse, Ny; Crouse Hosp, Syracuse, Ny
Group Practice: Urology Consultants-Syracuse

Data Provided by:
William Harrison Roberts, MD
(315) 479-6626
101 Union Avenue Ste 705 Physicians Office Bldg
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1969

Data Provided by:
Joseph F Finelli, MD
2 Brattle Rd
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Rochester Sch Of Med & Dentistry, Rochester Ny 14642
Graduation Year: 1953

Data Provided by:
Mark Allen Monsour, MD
(315) 424-0790
101 Union Ave Ste 614
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Louisville Sch Of Med, Louisville Ky 40202
Graduation Year: 1993
Hospital
Hospital: Miami Valley Hospital, Dayton, Oh
Group Practice: Urology Associates Of Dayton Inc

Data Provided by:
Mark LaSpina, DO
(315) 464-6106
750 E Adams St
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Andres Mihkel Madissoo, MD
(315) 637-2920
1226 E Water St
Syracuse, NY
Specialties
Urology
Gender
Male
Education
Medical School: Suny At Buffalo Sch Of Med & Biomedical Sci, Buffalo Ny 14214
Graduation Year: 1994

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com